Stockholder's equity | Stock options In March 2016, our Company granted options to purchase up to 3,517,067 shares of our common stock to members of our Board of Directors. The options vest immediately; have an exercise price of $0.12 per share; and expire five years after the date of grant. The fair value at grant date of these options was $246,141 and the entire amount was expensed in 2016. In March 2016, our Company granted options to purchase up to 1,459,326 shares of our common stock to four employees. The options vest over four years; have an exercise price of $0.12 per share; and expire five years after the date of grant. The fair value at grant date of these options was $112,147 and $48,145 was expensed in 2016. In March 2016, our Company granted options to purchase up to 1,859,623 shares of our common stock to thirty-three employees. The options vest immediately; have an exercise price of $0.11 per share; and expire five years after the date of grant. The fair value at grant date of these options was $142,006 and the entire amount was expensed in 2016. In May 2016, our Company granted options to purchase up to 264,000 shares of our common stock to Frank Liddy. The options vest immediately; have an exercise price of $0.08 per share; and expire five years after the date of grant. The fair value at grant date of these options was $20,256 and the entire amount was expensed in 2016. In May 2016, our Company granted options to purchase up to 450,000 shares of our common stock to two employees. The options vest over two years; have an exercise price of $0.06 per share; and expire five years after the date of grant. The fair value at grant date of these options was $17,979 and $8,088 was expensed in 2016. In June 2016, our Company granted options to purchase up to 2,104,751 shares of our common stock to thirty-two employees. The options vest immediately; have an exercise price of $0.09 per share; and expire five years after the date of grant. The fair value at grant date of these options was $151,431 and the entire amount was expensed in 2016. Effective July 22, 2016, the Company cancelled the following stock and stock options granted to its board of directors on March 21, 2016: (a) Joseph Proto, 350,000 restricted shares of common stock; (b) John Eyler, options to purchase 464,331 shares of common stock; (c) Pat Kolenik 350,000 restricted shares of common stock; (d) Chris Leong, options to purchase 464,331 shares of common stock, and (e) Isaac Blech, options to purchase 663,330 shares of common stock. In September 2016, our Company granted options to purchase up to 2,674,940 shares of our common stock to twenty-five employees. The options vest immediately; have an exercise price of $0.06 per share; and expire five years after the date of grant. The fair value at grant date of these options was $139,316 and the entire amount was expensed in 2016. In December 2016, our Company granted options to purchase up to 7,371,357 shares of our common stock to twenty-two employees. The options vest immediately; have an exercise price of $0.02 per share; and expire five years after the date of grant. The fair value at grant date of these options was $131,947 and the entire amount was expensed in 2016. In 2016, we expensed $222,357, related to the issuance of options from 2014 and 2015, that continued to vest in 2016. For the year ended December 31, 2015, we issued 3,666,476 options, as follows. During first quarter, 2015, our Company granted options to purchase up to 165,000 shares of our common stock to five employees. The options vest over four years; have exercise prices of $.90 to $.95 per share; and expire five years after the date of grant. The fair value at grant date of these options was $101,759. The amount expensed in 2015 was $21,564 and the amount expensed in 2016 was 16,142. On March 5, 2015, our Company granted options to purchase up to 360,000 shares of our common stock to members of our Board of Directors. The options vest immediately; have an exercise price of $0.92 per share; and expire five years after the date of grant. Each of the following Board members received 45,000 options each related to this issuance: Joe Proto, Isaac Blech, Alex Minicucci, Cary Sucoff, Patrick Kolenik, Chris Leong, Jerold Rubinstein, and Mike McCoy. The fair value at grant date of these options was $208,974 and the entire amount was expensed in 2015. In May 2015, our Company granted options to purchase up to 75,000 shares of our common stock to Bruce Neuschwander. The options vest over four years; have an exercise price of $0.65; and expire five years after the date of grant. The fair value at grant date of this option was $31,622. The amount expensed in 2015 was $10,794 and the amount expensed in 2016 was $3,763. On October 1, 2015, our Company granted options to purchase up to 1,358,696 shares of our common stock to Jerold Rubinstein. The options vest immediately; have an exercise price of $.46 per share; and expire five years after the date of grant. The fair value at grant date of these options was $410,559 and the entire amount was expensed in 2015. In November 2015, the Company repriced the 1,358,696 previously issued options to Jerold Rubinstein. The replacement stock options have an exercise price equal to $0.17 and a term of 4.8 years. The cancellation and reissuance of these stock options was treated as a modification under ASC 718 and, accordingly, total stock-based compensation expense related to these awards increased $35,713, which was recognized in 2015. In December, 2015, our Company granted options to purchase up to 278,500 shares of our common stock to four employees. The options vest immediately; have an exercise price of $.14 per share; and expire five years after the date of grant. The fair value at grant date of these options was $26,792 and the entire amount was expensed in 2015. In December, 2015, our Company granted options to purchase up to 70,584 shares of our common stock to five employees. The options vest immediately; have an exercise price of $.75 per share; and expire five years after the date of grant. The fair value at grant date of these options was $3,876 and the entire amount was expensed in 2015. Stock option activity during the following periods was as follows: For the year ended December 31, 2016 2015 Beginning balance outstanding 10,337,113 8,807,667 Options issued during the year 19,701,064 2,307,780 Options forfeited during the year (1,011,800 ) - Options cancelled during the year (1,591,992 ) - Options expired during the year (569,368 ) (778,334 ) Ending balance outstanding 26,865,017 10,337,113 Warrants The Company issued warrants to purchase shares of the Company’s common stock to investors in connection with the issuances of restricted shares of common stock during the years ended December 31, 2016 and 2015 (the value of which was offset against the proceeds of the issuance of common stock and not charged to operations). Outstanding warrants from all sources have terms ranging from two to five and a half years. For the year ended December 31, 2016, we did not issue any warrants to advisors, consultants and in connection with the purchase of intellectual property. Warrants to purchase up to 2,204,100 shares of common stock have expired. Warrants to purchase up to 1,981,667 shares of common stock remain outstanding at December 31, 2016, of which 1,981,667 have vested. For the year ended December 31, 2016, we issued 27,895,890 warrants to investors, of which 26,479,217 related to the Tender Offer above and 1,416,673 related to the Convertible Notes amendments above. 1,540,767 warrants expired and 12,270,853 warrants were exercised for the year ended December 31, 2016. In recompense for services performed on our behalf, we issued warrants to purchase up to 750,000 shares of our common stock during the year ended December 31, 2015, to Siskey Capital at an exercise price of $.75. 187,500 of those warrants vested immediately. On December 1, 2015, these warrants were repriced to an exercise price of $.17 and exercised on December 2, 2015, resulting in gross proceeds to the company of $127,500. Through December 31, 2015, we have also issued warrants to purchase up to 22,835,951 shares of our common stock to investors (and as compensation to third parties in connection with investments) related to the sale of our common stock, 26,397,410 of which remain outstanding net of exercises, cancellations and expirations (all of which are fully vested). On October 1, 2015, we issued 750,000 warrants to Siskey Capital for consulting services as noted above. 187,500 of those warrants vested immediately. Those 187,500 warrants were repriced on December 1, 2015 and the remaining 562,500 warrants were vested on December 1, 2015, with the full 750,000 warrants exercised on December 2, 2015. Warrants to purchase up to 118,858 shares of common stock have expired. Warrants to purchase up to 2,645,000 shares of common stock remain outstanding at December 31, 2015, of which 2,645,000 have vested. For the year ended December 31, 2015, we issued 1,983,340 warrants to new investors and 150,994 warrants had expired. Warrant activity (including warrants issued to investors and for consulting and advisory services) for the years ended December 31, 2016 and 2015 was as follows: For the twelve months ended December 31, 2016 2015 Beginning balance outstanding 26,397,410 23,933,922 Warrants issued during the year For consulting and advisory services - 1,500,000 In connection with sales of common, preferred stock, and notes 27,895,890 1,983,340 Warrants expired or cancelled during the year (2,204,100 ) (269,852 ) Warrants exercised (12,270,853 ) (750,000 ) Ending balance outstanding 39,818,347 26,397,410 The numbers and exercise prices of all options and warrants outstanding at December 31, 2016 was as follows: Shares Issuable Weighted Average Exercise Price Expiration Fiscal Period 34,749 7.99 1st Qtr, 2017 1,349,183 6.90 2nd Qtr, 2017 536,500 1.14 3rd Qtr, 2017 1,162,088 6.45 4th Qtr, 2017 10,000 6.60 1st Qtr, 2018 750,000 0.25 4th Qtr, 2018 37,504,567 0.37 1st Qtr, 2019 1,850,007 0.44 2nd Qtr, 2019 1,309,002 0.92 3rd Qtr, 2019 2,603,000 1.15 4th Qtr, 2019 480,000 0.92 1st Qtr, 2020 1,704,446 0.19 4th Qtr, 2020 4,785,376 0.12 1st Qtr, 2021 2,469,995 0.09 2nd Qtr, 2021 2,629,760 0.06 3rd Qtr, 2021 7,371,357 0.02 4th Qtr, 2021 133,334 7.05 4th Qtr, 2022 66,683,364 0.59 Stock based compensation Results of operations for the years ended December 31, 2016 and 2015 include stock based compensation costs totaling $1,084,323 and $1,807,337, respectively. For purposes of accounting for stock based compensation, the fair value of each option and warrant award is estimated on the date of grant using the Black-Scholes-Merton option pricing formula. Compensation expense is recognized upon actual vesting of the options. The following weighted average assumptions were utilized for the calculations during the year ended December 31, 2016 and 2015: For the years ended December 31, 2016 2015 Expected life (in years) 2.60 years 2.61 years Weighted average volatility 167.74 % 98.05 % Forfeiture rate 21.92 % 10.27 % Risk-free interest rate 1.05 % 0.95 % Expected dividend rate 0.00 % 0.00 % The weighted average expected option and warrant term for employee stock options granted reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, Share-Based Payment As of December 31, 2016, $696,544 of total unrecognized compensation cost related to unvested stock based compensation arrangements is expected to be recognized over a weighted-average period of 16.3 months. The following table summarizes option activity in connection with stock options and warrants (which resulted in stock based compensation charges) as of and for the years ended December 31, 2016 and 2015: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Instrinsic Shares Price Term Value Outstanding at December 31, 2015 12,982,113 $ 1.97 Granted 19,701,064 0.07 Cancelled (2,883,792 ) (0.29 ) Forfeited (952,701 ) (6.70 ) Exercised - - Outstanding at December 31, 2016 28,849,184 $ 0.68 45.8 months $ - Exercisable 26,735,358 $ 0.71 45.7 months $ - Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Instrinsic Shares Price Term Value Outstanding at December 31, 2014 10,821,525 $ 2.44 Granted 3,807,780 0.31 Cancelled (775,834 ) (0.92 ) Expired (118,858 ) (7.24 ) Exercised (750,000 ) (0.17 ) Outstanding at December 31, 2015 12,982,113 $ 1.98 39.9 months $ - Exercisable 11,711,738 $ 2.06 39.6 months $ - Additional disclosure concerning options and warrants is as follows: For the Year Ended December 31, Deccember 31, 2016 2015 Weighted average grant date fair value of options and warrants granted $ 0.05 $ 0.18 Aggregate intrinsic value of options and warrants exercised - - Weighted average fair value of options and warrants vested 0.43 0.66 The range of exercise prices for options and warrants granted and outstanding (which resulted in stock based compensation charges) was as follows at December 31, 2016 and 2015: Exercise Number of Options and Warrants Price December 31, December 31, Range 2016 2015 $ .01 - .74 $ 19,643,684 2,462,196 $ .75 - 1.20 $ 7,529,000 7,878,584 $ 1.21 - 3.00 $ 114,000 218,000 $ 3.01 - 4.50 $ - - $ 4.51 - 12.00 $ 1,560,000 2,423,333 28,846,684 12,982,113 A summary of the activity of our non-vested options and warrants for the following periods: For the year ended December 31, 2016 2015 Non-vested outstanding, beginning 1,270,375 3,285,639 Granted 19,701,064 3,807,780 Vested (17,238,203 ) (5,279,016 ) Forfeited (825,915 ) Cancelled (795,995 ) (544,028 ) Non-vested outstanding, ending 2,111,326 1,270,375 Common Shares Reserved for Future Issuance The following table summarizes shares of our common stock reserved for future issuance at December 31, 2016: December 31, December 31, 2016 2015 Stock options outstanding 26,865,017 10,337,113 Stock options available for future grant 9,437,000 9,437,000 Warrants 39,818,347 26,397,410 Total common shares reserved for future issuance 76,120,364 46,171,523 |